Elan Corp. and development partner Wyeth have suspended a mid-stage clinical trial of ACC-001, an experimental Alzheimer’s vaccine, in order to look into a potentially serious side effect suffered by a patient in the study.     Dosing in the study was stopped after the patient was hospitalized with skin lesions. The physician serving as lead researcher suspected it to be a case of vasculitis, an inflammation of blood vessels.        “Following discussion with the FDA, all furth...